---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-026968"
form_type: "8-K"
ticker: "OGEN"
cik: "0001174940"
company_name: "ORAGENICS INC"
filed_at: "2023-08-07T23:59:59+00:00"
generated_at: "2026-06-12T03:46:59.264233+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Oragenics raises ~$840K in private placement; issues Series E Preferred with super voting rights

## Summary
- Gross proceeds of approximately $840,000 from issuance of 404,728 shares of common and 404,728 shares of Series E Preferred.
- Series E Preferred carries 2,500 votes per share solely to approve a proposed amendment increasing authorized common from 4,166,666 to 350,000,000.
- Series E Preferred automatically cancelled upon effectiveness of the amendment; no dividends and no trading market.
- Net proceeds to be used for general corporate purposes; offering closed August 4, 2023.
- Investors have agreed to vote Series E in the same proportion as common shares on the amendment.

## SEC filing metadata
- accession: 0001493152-23-026968
- form_type: 8-K
- ticker: OGEN
- cik: 0001174940
- company_name: ORAGENICS INC
- filed_at: 2023-08-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 5.03, 3.02, 3.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1174940/000149315223026968/0001493152-23-026968-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1174940/000149315223026968/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-026968
- JSON: https://secwatch.observer/filing/0001493152-23-026968.json
- Plain text: https://secwatch.observer/filing/0001493152-23-026968.txt

## Key facts
- Governance Changes
  ORAGENICS INC: Filed Certificate of Designation creating Series E Preferred Stock with specific voting and liquidation terms, contingent on an Amendment.
  - Change: charter amendment
  source text: In connection with the Offering, the Company filed a Certificate of Designation with the Secretary of State for the State of Florida (the “Certificate of Designation”) designating 404,728 shares out of the authorized but unissued shares of its preferred stock as Series E Preferred Stock.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1174940/000149315223026968/0001493152-23-026968-index.htm
- Material Agreements
  ORAGENICS INC entered into Securities Purchase Agreement with two healthcare-focused investors (effective 2023-08-04).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: two healthcare-focused investors
  - Effective: 2023-08-04
  source text: On August 4, 2023, Oragenics, Inc. (the "Company") entered into a Securities Purchase Agreement (the "Purchase Agreement") with two healthcare-focused investors, pursuant to which the Company agreed to issue in a private placement (the "Offering"), an aggregate of (i) 404,728 shares of the Company’s common stock, $0.001 par value (the "Common Stock"), and (ii) 404,728 shares of Series E Mirroring Preferred Stock
  evidence_url: https://www.sec.gov/Archives/edgar/data/1174940/000149315223026968/0001493152-23-026968-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.